Cue Biopharma Secures Preclinical Milestone Payment
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced on April 8, 2026, that it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim under their existing collaboration and license agreement. According to GlobeNewswire PE, this payment follows Boehringer Ingelheim’s selection and approval of its first compound for lead optimization, with Cue Biopharma expecting to receive the funds in May 2026.
The Milestone in Context
Lucinda Warren, interim president and chief executive officer of Cue Biopharma, stated that the company has achieved this critical preclinical milestone through its strategic research collaboration with Boehringer Ingelheim. Under the terms of the agreement, Cue Biopharma’s technology will be used to further research and advance the development of the candidate molecule, specifically focusing on CUE-501, a bispecific molecule intended for autoimmune and inflammatory diseases. The collaboration also includes provisions for expanding research and development into various B cell targeting bispecifics for autoimmune diseases.
Details of the Collaboration Agreement
The multi-year collaboration and license agreement with Boehringer Ingelheim enables Cue Biopharma to leverage its Immuno-STAT platform to develop therapeutics that selectively engage memory T cell subsets to deplete pathogenic B cells. According to GlobeNewswire PE, Cue Biopharma is eligible for up to approximately $337.5 million in additional research, development, and commercial milestone-based payments, as well as royalty payments on net sales of resulting products. This structure supports the advancement of Cue Biopharma’s lead autoimmune asset, CUE-401, which is designed as a bifunctional molecule combining a TGF-beta moiety with an interleukin 2 mutein.
About Cue Biopharma
Cue Biopharma is developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases. The company’s Immuno-STAT biologics are intended to harness the body’s immune system without broad systemic effects, with CUE-401 acting as a regulator of proinflammatory mechanisms and a switch for regulatory T cell differentiation. As a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, Cue Biopharma is led by an experienced management team focused on advancing its pipeline, according to GlobeNewswire PE.
